The single dose ascending trial was conducted in patients with chronic hepatitis C virus (HCV) who have either failed or no longer respond to standard of care treatment.
Findings are expected to support the initiation of repeat dose and combination therapy trials later this year. Top-line safety data from the study is due to be presented at the viral hepatitis in drug discovery and development meeting in Boston on February 27, 2006.
Tarvacin anti-viral is a monoclonal antibody with unique anti-viral properties that is in preclinical studies for pandemic and seasonal influenza, cytomegalovirus, HIV and biodefense applications. Tarvacin is also in phase I clinical trials for the treatment of advanced refractory solid cancers.
“Completing this first HCV study of Tarvacin anti-viral ahead of schedule is enabling us to accelerate plans for future clinical studies and for new collaborations with clinical sites,” said Steven King, president and CEO of Peregrine.